Ads
related to: first line therapy for metastatic lung cancer- 2L mNSCLC Treatment
For Metastatic
NSCLC. Visit Physician Site.
- Efficacy & Safety Data
See If A 2L mNSCLC Treatment
Is An Option For Your Patients.
- mNSCLC Biomarker Info
Discover A Treatment For 2L mNSCLC
With This Actionable Biomarker
- Resources For Physicians
Downloadable Resources For Your
mNSCLC Patients & Their Caregivers.
- Dosing & Administration
View Dosing & Preparation Info For
A 2L mNSCLC Treatment Option.
- Mechanism Of Action Info
See How A 2L Metastatic
NSCLC Therapy Works.
- 2L mNSCLC Treatment
Search results
Results From The WOW.Com Content Network
In 2021, the FDA approved amivantamab as the first treatment for patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutation. [50] [51] The first line treatment of advanced/metastatic NSCLC can incorporates immunotherapy either as a single modality or with chemotherapy. [16]
In May 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cejemly, intended for the first-line treatment of metastatic non-small cell lung cancer in combination with chemotherapy.
In March 2024, the FDA approved amivantamab, in combination with carboplatin and pemetrexed, for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. [11]
In November 2017, the FDA approved alectinib for the first-line treatment of people with ALK-positive metastatic non-small cell lung cancer. [16] This based on the phase 3 ALEX trial comparing it with crizotinib. [16]
Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...
Rybrevant and Lazcluze showed significant improvement in overall survival in first-line treatment of advanced or metastatic non-small cell lung cancer. We received FDA approval of Spravato as the ...
In May 2020, the atezolizumab was approved by the FDA for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no ...
In lung cancer, Trodelvy continues to be evaluated in combination with pembro in first-line PD-L1 high metastatic nonsmall cell lung cancer in the phase 3 EVOKE-03 study.
Ads
related to: first line therapy for metastatic lung cancer